In another example in prostate cancer, IRE and anti-CTLA-4 increased intratumoral tumor-specific T cells and increased tissue-resident CD8+ memory T cells (TRM) in non-lymphoid tissues including skin. This evidence concerns the gene CD8A and prostate carcinoma.